



ADULT MEDICATION GUIDELINE

LINEZOLID

| | |
|-----------------------|----------------------------|
| Scope (Staff): | All WNHS Staff |
| Scope (Area): | Obstetrics and Gynaecology |

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Highly Restricted \(IV and oral mixture\)](#)

[Formulary: Restricted \(oral\)](#)

Antibacterial

Presentation

IV infusion bag: 600mg/300mL

Oral: 600mg tablet

Oral suspension: 100mg/5mL

Storage

Store at room temperature, below 25°C

IV - Keep bags in foil over-wrap until ready to use. Once opened, use immediately.

Dose

Serious infections due to Gram-positive organisms where other agents are unsuitable

IV:

600mg every 12 hours

Oral:

400-600mg every 12 hours

Administration

Refer to the [Australian Injectable Drugs Handbook](#)

Monitoring

Avoid tyramine rich foods as blood pressure may elevate

Monitor for tingling or altered sensation, blurred vision

Monitor complete blood count each week if using for >2 weeks

Pregnancy

1st Trimester: Consider alternative*

2nd Trimester: Consider alternative*

3rd Trimester: Consider alternative*

*Limited information; single case reports of healthy infants following second trimester maternal use. Has not caused congenital malformations in animals.

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Consider alternative*

*RID between (7.8 - 15.6%). Anticipated infant dose well below recommended neonatal dosing

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Comments

Treatment with inhibitors of MAO-A or -B (or within 2 weeks of such treatment)—contraindicated by manufacturer (linezolid is a weak, reversible, nonselective MAOI).

Treatment with drugs that may contribute to serotonin toxicity—likelihood of serotonin toxicity is increased as linezolid is a weak MAOI; avoid combinations or monitor carefully.

Uncontrolled hypertension, phaeochromocytoma, thyrotoxicosis—BP may increase; avoid use or monitor carefully.

Linezolid has near 100% oral bioavailability. Consider switching to tablets if the patient is stable and can tolerate medicines orally.

Related Policies, Procedures & Guidelines

HDWA Mandatory Policies:

[Formulary ONE](#)

WNHS Policies:

[Antimicrobial Stewardship](#)

[Antimicrobial Restriction Category List](#)

References

Australian Medicines Handbook. Linezolid. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Apr11]

Therapeutic Guidelines. Staphylococcal pneumonia. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2022 [cited 2022 Apr11] Available from: <https://tgldcdp.tg.org.au>

Truven Health Analytics. Linezolid. In: Micromedex [Internet]. Greenwood Village (CO): Truven Health Analytics; 2022 [cited 2022 Apr11]

Society of Hospital Pharmacists of Australia. Linezolid. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2022 Apr11] Available from: <http://aidh.hcn.com.au>

Hale TW. Linezolid. In: Medications and Mothers' Milk [Internet]. New York: Springer Publishing Company; 2022 [cited 2022 Apr11] Available from: <http://www.medsmilk.com>

The Royal Women's Hospital. Linezolid. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 Apr11] Available from: <https://thewomenspbmg.org.au/>

| | | | | | |
|---|--|----------------|---|--------------|------------|
| Keywords | Linezolid, gram-positive infection, MRSA, VRE | | | | |
| Document Owner: | Chief Pharmacist | | | | |
| Author/ Reviewer | KEMH Pharmacy Department | | | | |
| Version Info: | 4.0 | | | | |
| Date First Issued: | March 2014 | Last Reviewed: | 11/04/2022 | Review Date: | 11/04/2025 |
| Endorsed by: | Medicines and Therapeutics Committee | | | Date: | 05/07/2022 |
| NSQHS Standards Applicable: | <input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety | | <input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint. | | | | | |

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.